Iterum Therapeutics Q1 net loss $4.9M; preparing for ORLYNVAH launch by Q4 2025

Iterum Therapeutics plc

Net loss of $4.9M in Q1 2025 vs $7.1M in Q1 2024; non-GAAP net loss $3.3M vs $5.8M.
Cash and equivalents $12.7M at March 31, 2025; extended runway into 2026 via $5M registered direct offering and ~$1M ATM proceeds.
Preparing for potential launch of ORLYNVAH (oral sulopenem) for uUTIs by Q4 2025; FDA approved October 2024.
Repaid $6.5M 6.500% exchangeable senior subordinated notes due 2025 in January 2025.
R&D expense fell to $0.6M (from $4.0M) due to REASSURE trial wind-down; G&A rose to $2.8M on pre-commercialization costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.